THERAPY DOSSIER · th-bfe8f2a667f0

Testosterone

Hormone · Androgen receptor agonist (AGONIST, direct interaction, disease efficacy true). ChEMBL flags a black box warning for this molecule.

No trauma translation Suggest a correction

This record is classified as “NO TRAUMA TRANSLATION”. Read the indication and notes below for the specific context.

Evidence & regulatory context

Mechanism: Androgen receptor agonist (AGONIST, direct interaction, disease efficacy true). ChEMBL flags a black box warning for this molecule.
Target: CHEMBL1871 (Androgen Receptor)
Injury models: Spinal cord injury
Reported indication: Not recorded
First approval: 1972
Development stage: Not recorded
ChEMBL record: CHEMBL386630 ↗
ChEMBL max phase: 4 / 4 (development scale, not regulatory approval)
Synonyms: Testosterone; Androgel; Androderm; Testim; Testogel; Natesto; Axiron; Fortesta; Striant; Testopel; Vogelxo; Tostran; Intrinsa; NSC-9700
Note: Not recorded

Clinical trials 5

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT01403116 ↗PHASE3completed

Oral testosterone undecanoate vs topical testosterone gel in hypogonadal men

Male Hypogonadism

Enrolment: 325 · Results not recorded

NCT01310647 ↗PHASE2completed

Testosterone or estradiol antral follicle priming before IVF-ICSI in low responders

Ovarian Diseases

Enrolment: 66 · Results not recorded

NCT03116087 ↗NAcompleted

Testosterone replacement in postmenopausal women with stress urinary incontinence

Stress Urinary Incontinence

Enrolment: 60 · Results not recorded

NCT00847314 ↗Phase not recordedcompleted

Testogel/Nebido with exercise and diet in hypogonadal men with abdominal obesity

Hypogonadism

Enrolment: 30 · Results not recorded

NCT04342247 ↗Phase not recordedcompleted

Effects of external testosterone intake on the choroid

Androgen Deficiency

Enrolment: 30 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 21931329 ↗2011Reported benefit

Testosterone reduced methylprednisolone-induced muscle atrophy in spinal cord-injured rats.

RatSpinal cord injuryComplete transectionWistarMaleInfusionOver 7 days after injury

Model: Complete spinal cord transection with methylprednisolone-induced muscle atrophy

Testosterone partially protected against methylprednisolone-induced muscle atrophy and atrophy gene upregulation but did not fully prevent it.

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.75. Machine-extracted fields require source verification.

Loading the evidence…